Roche: discontinuation of dosing in tominersen study
(CercleFinance.com) - Roche announced on Monday evening its decision to discontinue dosing in the phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD), following the recommendation of an independent data monitoring committee.
The decision is based on the results of a pre-planned review of the study data by this committee, which made its recommendation based on the potential benefit/risk profile of the investigational treatment for participants in the study.
No new or emerging safety signals were identified during the data review. Roche intends to continue to monitor participants for safety and clinical outcomes, without the dosing of the investigational drug or placebo.
Roche shares are down over 1.5% in Zurich on Tuesday afternoon, while the Swiss market is up about 0.3%
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The decision is based on the results of a pre-planned review of the study data by this committee, which made its recommendation based on the potential benefit/risk profile of the investigational treatment for participants in the study.
No new or emerging safety signals were identified during the data review. Roche intends to continue to monitor participants for safety and clinical outcomes, without the dosing of the investigational drug or placebo.
Roche shares are down over 1.5% in Zurich on Tuesday afternoon, while the Swiss market is up about 0.3%
Copyright (c) 2021 CercleFinance.com. All rights reserved.